Publication Date
2014
Journal Title
Lupus Sci Med
Abstract
OBJECTIVE: Correlates of systemic lupus erythematosus (SLE) Responder Index (SRI) response with clinical trial end points were examined using pooled data from the Study of Belimumab in Subjects with SLE (BLISS) trials (N=1684). METHODS: Changes in clinical, laboratory and health-related quality of life measures from baseline at 52 weeks were compared between SRI responders (n=761) and non-responders (n=923). RESULTS: More SRI responders than non-responders had >/=4-point (100% vs 3.8%) and >/=7-point (40.3% vs 1.3%) Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index reductions, no new British Isles Lupus Assessment Group (BILAG) A and7.5 mg/d to7.5 mg/d (4.1% vs 21.3%; all p
Volume Number
1
Issue Number
1
Pages
e000031
Document Type
Article
EPub Date
2014/11/15
Status
Faculty
Facility
School of Medicine
Primary Department
Rheumatology
PMID
DOI
10.1136/lupus-2014-000031